Sex differences in the neurobiology of drug addiction

Bobzean, Samara A.M.; Nobrega, Aliza K. De; Perrotti, Linda I.

doi:10.1016/j.expneurol.2014.01.022

Cited by 229 publications

(172 citation statements)

References 214 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…Males failed pre-screening more than females: the majority of candidates who failed due to substance dependence were male (88%), similar to rates reported elsewhere (12). Of note, most substance-dependent males (84%) were cocaine-dependent concurrent with marijuana-dependence, in contrast to other studies in the general population, which described up to 23% of concomitant dependence to both substances (13).…”

Section: Discussionsupporting

confidence: 87%

The Value of Pre-Screening in the Alzheimer’s Prevention Initiative (Api) Autosomal Dominant Alzheimer’s Disease Trial

et al. 2017

View full text Add to dashboard Cite

The Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds. The pre-screening failure rate was 48.2%: the primary reason was expected inability to comply with the protocol, chiefly due to work requirements. More carriers compared to non-carriers, and more males compared to females, failed pre-screening. Carriers with illiteracy or learning/comprehension difficulties failed pre-screening more than non-carriers. With the Colombian API Registry and our prescreening efforts, we randomized 169 30-60 year-old cognitively unimpaired carriers and 83 non-carriers who agreed to participate in the trial for at least 60 months. Our findings suggest multiple benefits of implementing a pre-screening process for enrolling prevention trials in ADAD.

show abstract

Section: Discussionsupporting

confidence: 87%

The Value of Pre-Screening in the Alzheimer’s Prevention Initiative (Api) Autosomal Dominant Alzheimer’s Disease Trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Studying all prevalent PPR users cross-sectionally, Becker et al, (2008) and Novak et al, (2009) As for female-male differences, there is a relatively limited epidemiology trace of published estimates (e.g, Bobzean et al, 2014;Chen and Kandel, 2002;Kasperski et al, 2011;Sartor et al, 2014). Overall, for cocaine, these investigations suggest that women, in the past, have been less likely to become newly incident cocaine users, and that there has been no pronounced female-male difference in the probability of transitioning from initial cocaine use into the clinically significant state of cocaine dependence (e.g., see Wagner and Anthony, 2007).…”

Section: How Well Do Our Hill Equation Parameter Estimates For Newly mentioning

confidence: 99%

Transitioning from First Drug Use to Dependence Onset: Illustration of a Multiparametric Approach for Comparative Epidemiology

Vsevolozhskaya

Anthony

2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Studying transitions from first drug use (DU) to drug dependence (DD) onset, we estimate a parsimonious set of parameters based on epidemiological data, with plans for future longitudinal research on newly incident drug users and with tracking of self-administration frequencies and DD clinical features. Our expectation is a distinctive sigmoid pattern with one asymptote for lower DD probability (when DU is insubstantial), upturning slopes of DD risk beyond a middle value (PD50), and eventual higher DD risk asymptotes at higher DU frequencies. We illustrate this novel approach using cross-sectional data from the United States National Surveys on Drug Use and Health, 2002-2011. Empirical DD probabilities observed soon after newly incident use are estimated across DU frequency values, using parametric Hill functions and four governing parameters for differential comparison across drugs and DU subgroups. Among drug subtypes considered, cocaine shows larger estimates, especially among females (estimated P(min)=7% for females vs 3% for males; p<0.001), for whom PD50 is shorter by 8 days of use (p=0.027), conditional on the same rate of use in the past 30 days. Clear alcohol male-female differences also are observed (eg, female PD50 < male PD50; p=0.002). Although based on cross-sectional snapshots soon after DU onset, this novel multiparametric statistical approach for comparative epidemiological DD research creates new opportunities in planned studies with prospectively gathered longitudinal data. The cross-sectional estimates provide starting values needed to plan future longitudinal research programs on transitions from initial DU until formation of a DD syndrome.

show abstract

“…This is a small but growing area. Numerous genes including cytochrome 2A6, which degrades nicotine, genes related to dopamine function (especially monoamine oxidase which is X-linked), as well as opiate GABA and glutamate receptors are involved (Ahijevych, 1999; Becker & Hu, 2008; Bobzean, DeNobrega, & Perrotti, 2014; Enoch, 2003; Enoch & Goldman, 2001; Kreek et al, 2012; Nielsen & Kreek, 2012; Reed, Butelman, Yuferov, Randesi, & Kreek, 2014; Satarug, Tassaneeyakul, Na-Bangchang, Cashman, & Moore, 2006; Seeman, 2009; Tsankova, Renthal, Kumar, & Nestler, 2007). As our understanding of how these genetic influences contribute to the emergence of sex differences in substance use and abuse is marginal, we will not consider this important topic further.…”

Section: Sex/gender Differences In the Neurobiology Of Addictionmentioning

confidence: 99%

Emergence of sex differences in the development of substance use and abuse during adolescence

Kuhn

2015

Pharmacology & Therapeutics

147

109

View full text Add to dashboard Cite

Substance use and abuse begins during adolescence. Male and female adolescent humans initiate use at comparable rates, but males increase use faster. In adulthood, more men than women use and abuse addictive drugs. However, some women progress more rapidly from initiation of use to entry into treatment. In animal models, adolescent males and females consume addictive drugs similarly. However, reproductively mature females acquire self-administration faster, and in some models, escalate use more. Sex/gender differences exist in neurobiologic factors mediating both reinforcement (dopamine, opioids) and aversiveness (CRF, dynorphin), as well as intrinsic factors (personality, psychiatric co-morbidities) and extrinsic factors (history of abuse, environment especially peers and family) which influence the progression from initial use to abuse., Many of these important differences emerge during adolescence, and are moderated by sexual differentiation of the brain. Estradiol effects which enhance both dopaminergic and CRF-mediated processes contribute to the female vulnerability to substance use and abuse. Testosterone enhances impulsivity and sensation seeking in both males and females. Several protective factors in females also influence initiation and progression of substance use including hormonal changes of pregnancy as well as greater capacity for self-regulation and lower peak levels of impulsivity/sensation seeking. Same sex peers represent a risk factor more for males than females during adolescence, while romantic partners increase risk for women during this developmental epoch. In summary, biologic factors, psychiatric co-morbidities as well as personality and environment present sex/gender-specific risks as adolescents begin to initiate substance use.

show abstract

Sex differences in the neurobiology of drug addiction

Cited by 229 publications

References 214 publications

The Value of Pre-Screening in the Alzheimer’s Prevention Initiative (Api) Autosomal Dominant Alzheimer’s Disease Trial

The Value of Pre-Screening in the Alzheimer’s Prevention Initiative (Api) Autosomal Dominant Alzheimer’s Disease Trial

Transitioning from First Drug Use to Dependence Onset: Illustration of a Multiparametric Approach for Comparative Epidemiology

Emergence of sex differences in the development of substance use and abuse during adolescence

Contact Info

Product

Resources

About